Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Sold by Natixis Advisors LLC

Natixis Advisors LLC lowered its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 3.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 50,910 shares of the biopharmaceutical company’s stock after selling 1,652 shares during the period. Natixis Advisors LLC’s holdings in Ultragenyx Pharmaceutical were worth $2,142,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Swiss National Bank raised its position in Ultragenyx Pharmaceutical by 2.5% during the fourth quarter. Swiss National Bank now owns 163,152 shares of the biopharmaceutical company’s stock worth $6,864,000 after acquiring an additional 4,000 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in Ultragenyx Pharmaceutical by 28.7% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 22,874 shares of the biopharmaceutical company’s stock worth $962,000 after acquiring an additional 5,104 shares during the last quarter. AlphaQuest LLC raised its position in Ultragenyx Pharmaceutical by 280.7% during the fourth quarter. AlphaQuest LLC now owns 8,167 shares of the biopharmaceutical company’s stock worth $344,000 after acquiring an additional 6,022 shares during the last quarter. E Fund Management Co. Ltd. raised its position in Ultragenyx Pharmaceutical by 13.9% during the fourth quarter. E Fund Management Co. Ltd. now owns 7,200 shares of the biopharmaceutical company’s stock worth $303,000 after acquiring an additional 877 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new position in Ultragenyx Pharmaceutical during the fourth quarter worth about $916,000. Institutional investors and hedge funds own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical Stock Performance

Ultragenyx Pharmaceutical stock opened at $39.18 on Monday. Ultragenyx Pharmaceutical Inc. has a 1 year low of $37.02 and a 1 year high of $60.37. The firm has a 50 day moving average price of $41.88 and a 200 day moving average price of $47.38. The company has a market cap of $3.62 billion, a price-to-earnings ratio of -6.18 and a beta of 0.67.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($1.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.32) by ($0.07). Ultragenyx Pharmaceutical had a negative net margin of 101.60% and a negative return on equity of 193.80%. The company had revenue of $164.88 million during the quarter, compared to analysts’ expectations of $163.23 million. Sell-side analysts predict that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current year.

Insiders Place Their Bets

In other Ultragenyx Pharmaceutical news, EVP Karah Herdman Parschauer sold 2,990 shares of the business’s stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $42.88, for a total transaction of $128,211.20. Following the completion of the sale, the executive vice president now directly owns 54,991 shares in the company, valued at $2,358,014.08. The trade was a 5.16 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Emil D. Kakkis sold 73,434 shares of the business’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $42.10, for a total transaction of $3,091,571.40. Following the sale, the chief executive officer now owns 641,731 shares of the company’s stock, valued at approximately $27,016,875.10. This represents a 10.27 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 136,370 shares of company stock worth $5,751,499 over the last ninety days. 5.80% of the stock is owned by company insiders.

Analysts Set New Price Targets

RARE has been the subject of a number of research reports. Cantor Fitzgerald restated an “overweight” rating and set a $118.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, February 26th. Wedbush reiterated a “neutral” rating and set a $48.00 price target (up from $46.00) on shares of Ultragenyx Pharmaceutical in a report on Monday, January 13th. Piper Sandler lowered their price target on shares of Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an “overweight” rating for the company in a report on Monday, March 17th. Canaccord Genuity Group lifted their price target on shares of Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the stock a “buy” rating in a report on Tuesday, February 18th. Finally, HC Wainwright reiterated a “buy” rating and set a $95.00 price target on shares of Ultragenyx Pharmaceutical in a report on Friday, February 14th. One investment analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $91.71.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.